Myomo, Inc. (MYO) Stock

Myomo, Inc. (MYO) is a Healthcare stock trading at $1.75 (as of 2026-08-20), with a market capitalization of $67.62M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Myomo, Inc. designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. Its MyoPro myoelectric-controlled upper-limb brace supports weak or paralyzed arms for functional activities and is sold to orthotics and prosthetics providers, the Veterans Health Administration, rehabilitation hospitals, and through distributors.

Understand Myomo, Inc.: how it makes money

Myomo designs, develops, and produces the MyoPro wearable myoelectric upper limb brace (orthosis) for people with neuromuscular disorders, and it makes money by selling that device used to support weak or paralyzed arms in daily living.

The profit engine is pipeline conversion, moving medically qualified patients through the MyoPro pipeline until orders and insurance authorizations are received, which then drives shipped MyoPro revenue units.

Revenue by segment (latest quarter)
MyoPro$0.0B
US Orthotics Channel$0.0B

Business quality (Weak): Useful operating KPIs are provided (pipeline and orders with authorizations), but revenue is reported as 0.0B in the latest quarter, limiting how directly we can tie segments to profitability from the data shown.

Bull case

  • Strong gross margin in the latest quarter: Gross margin was 68.2% for the quarter ended 2026-03-31.
  • Healthy pipeline scale: The company reported 1669 Patient Pipeline Patients in Process of Obtaining a MyoPro, indicating ongoing demand capture before authorization and order receipt.
  • Some recurring patient sources: Recurring Patient Sources Percentage of Revenue was 49%.

Bear case

  • Loss-making operations: Operating margin was -31.2% for the quarter ended 2026-03-31.
  • Pipeline conversion gap: The company reported 1669 patients in process versus 239 MyoPro units with orders and insurance authorizations received, suggesting meaningful work remains before those patients become recognized orders.
  • Payer concentration risk: Medicare Part B Patients Percentage of Revenue was 49%, and Revenue from Medicare Part B Patients was 56% in the quarter ended 2026-03-31.
Valuation — source: SEC EDGAR (first-party)
Price$1.75
Market Cap$67.62M
Price / Book7.51
Price / Sales1.70
FCF Yield-52.8%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$40.93M
Net Margin-38.1%
Revenue Growth (YoY)25.7%
EPS Growth (YoY)131.3%
FCF Growth (YoY)249.5%
Financial Health — source: SEC EDGAR
Altman Z-Score-2.39 (distress)
Piotroski F-Score4/9 (moderate)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderRosalind Advisors, Inc. ($2.60M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEOPaul R. Gudonis
Employees184
CountryUS
IPO Date2017-06-12

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Sanara MedTech Inc. (SMTI)
  • Conexeu Sciences Inc. (CNXU)
  • Inogen, Inc. (INGN)
  • Lakeland Industries, Inc. (LAKE)
  • Safe Pro Group Inc. Common Stock (SPAI)
  • Nutriband Inc. (NTRB)
  • Milestone Scientific Inc. (MLSS)
  • Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)
MYO earnings history · MYO institutional & insider holders · MYO KPIs & operating metrics · MYO financials · MYO investor presentations & press releases · MYO SEC filings · MYO peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.